Publications by Emeritus Professor Philip Home - ePrints

Browsing publications by Emeritus Professor Philip Home.

Newcastle Authors	Title	Year
Emeritus Professor Philip Home	Insulin biobetters and biosimilars in clinical practice	2023
Emeritus Professor Philip Home	Making sense of weekly insulins	2023
Emeritus Professor Philip Home	Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial	2022
Emeritus Professor Philip Home	Insulin therapy development beyond 100 years	2022
Emeritus Professor Philip Home	Understanding Biosimilar Insulins - Development, Manufacturing, and Clinical Trials	2022
Emeritus Professor Philip Home	Can we find out if COVID-19 causes diabetes?	2021
Emeritus Professor Philip Home	Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison	2021
Emeritus Professor Philip Home	Future directions in insulin therapy	2021
Emeritus Professor Philip Home	Heart failure management; a perspective from diabetes care	2021
Emeritus Professor Philip Home	Lingering effects of hyperglycemia in recently diagnosed diabetes during long-term follow-up of the dcct/edic and ukpds cohorts: More evidence that early control matters	2021
Emeritus Professor Philip Home	Tackling obesity during the COVID-19 pandemic	2021
Emeritus Professor Philip Home	The evolution of insulin therapy	2021
Emeritus Professor Philip Home	Comparison of multiple cut points for time in range in relation to risk of abnormal carotid intima-media thickness and diabetic retinopathy	2020
Emeritus Professor Philip Home	Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon‐like peptide‐1 receptor agonists: a systematic literature review and indirect treatment comparison.	2020
Emeritus Professor Philip Home	How Valid Are the New Hypoglycemia Definitions for Use in Clinical Trials?	2020
Emeritus Professor Philip Home	Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C-peptide levels in insulin-naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial	2020
Emeritus Professor Philip Home	Impact of a weekly glucagon-like peptide 1 receptor agonist, albiglutide, on glycemic control and on reducing prandial insulin use in type 2 diabetes inadequately controlled on multiple insulin therapy: A randomized trial	2020
Emeritus Professor Philip Home	Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis	2020
Emeritus Professor Philip Home	Is Insulin Therapy Safe?	2020
Emeritus Professor Philip Home	Cardiovascular outcome trials of glucose-lowering medications: an update	2019
Emeritus Professor Philip Home	Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0%	2019
Emeritus Professor Philip Home	Controversies for Glucose Control Targets in Type 2 Diabetes: Exposing the Common Ground	2019
Emeritus Professor Philip Home	Determination of fasiglifam-induced liver toxicity: Insights from the data monitoring committee of the fasiglifam clinical trials program	2019
Emeritus Professor Philip Home	The Need for Accuracy in Hemoglobin A1c Proficiency Testing: Why the Proposed CLIA Rule of 2019 Is a Step Backward	2019
Emeritus Professor Philip Home	2020 vision – An overview of prospects for diabetes management and prevention in the next decade	2018
Emeritus Professor Philip Home	A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes	2018
Emeritus Professor Philip Home	Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes	2018
Emeritus Professor Philip Home	Assessment of hypoglycaemia during basal insulin therapy: Temporal distribution and risk of events using a predefined or an expanded definition of nocturnal events	2018
Emeritus Professor Philip Home	Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study	2018
Emeritus Professor Philip Home	Comment on Novodvorsky et al. Diurnal Differences in Risk of Cardiac Arrhythmias During Spontaneous Hypoglycemia in Young People With Type 1 Diabetes. Diabetes Care 2017;40:655–662	2018
Emeritus Professor Philip Home	Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial	2018
Emeritus Professor Philip Home	Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial	2018
Emeritus Professor Philip Home	Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4)	2018
Emeritus Professor Philip Home	Need for regulatory change to incorporate beyond A1C glycemic metrics	2018
Emeritus Professor Philip Home	A diabetes mellitus guideline gone wrong - the 2017 ACP update	2017
Emeritus Professor Philip Home	Comment on Abd El Aziz et al., A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients	2017
Emeritus Professor Philip Home	Comment on Severe hypoglycemia requiring medical intervention in a large cohort of adults with diabetes receiving care in U.S. integrated health care delivery systems 2005–2011. Diabetes Care 2016: 39; 363–370	2017
Emeritus Professor Philip Home	Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial	2017
Emeritus Professor Philip Home	Incorporating Site-Less Clinical Trials Into Drug Development: A Framework for Action	2017
Emeritus Professor Philip Home	Insulin regimens and glycemic control in different parts of Europe over 4 years after starting insulin in people with type 2 diabetes: Data from the CREDIT non-interventional study	2017
Emeritus Professor Philip Home	Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting	2017
Emeritus Professor Philip Home	Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy	2017
Emeritus Professor Philip Home	A clinically defined nocturnal window for analysis of hypoglycemia: New insulin glargine 300U/ML (GLA-300) in type 2 diabetes (T2DM)	2016
Emeritus Professor Philip Home	Clinical use of the co-formulation of insulin degludec and insulin aspart	2016
Emeritus Professor Philip Home	Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes	2016
Emeritus Professor Philip Home	Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?	2016
Emeritus Professor Philip Home	IDegAsp (insulin degludec + insulin aspart) for the management of type 2 diabetes: current status	2016
Emeritus Professor Philip Home	Relationship of glycaemic control and hypoglycaemic episodes to 4-year cardiovascular outcomes in people with type 2 diabetes starting insulin	2016
Emeritus Professor Philip Home	A common fallacy of observational medication studies in diabetes	2015
Emeritus Professor Philip Home	Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum	2015
Emeritus Professor Philip Home	Albiglutide provides effective glycaemic lowering across diabetes duration subgroups	2015
Emeritus Professor Philip Home	An analysis of the cost-effectiveness of starting insulin detemir in insulin-naive people with type 2 diabetes	2015
Emeritus Professor Philip Home	An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins	2015
Emeritus Professor Philip Home	Biosimilar insulins: guidance for data interpretation by clinicians and users	2015
Emeritus Professor Philip Home	Cancer and bone fractures in observational follow-up of the RECORD study	2015
Emeritus Professor Philip Home	Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research	2015
Dr Augustin Brooks Emeritus Professor Philip Home Dr Nick Steen Professor James Shaw	Demonstration of an Intrinsic Relationship Between Endogenous C-Peptide Concentration and Determinants of Glycemic Control in Type 1 Diabetes Following Islet Transplantation	2015
Emeritus Professor Philip Home	Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5	2015
Emeritus Professor Philip Home	Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents	2015
Emeritus Professor Philip Home	Glycemic Control and Hypogycemia with New Insulin Glargine 300 U/ML in People with Type 1 Diabetes (Edition 4)	2015
Emeritus Professor Philip Home	Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes	2015
Emeritus Professor Philip Home	New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)	2015
Emeritus Professor Philip Home	New Insulin Glargine 300 U/ML: Efficacy and Safety of Flexible vs Fixed Dosing Intervals in People with Type 2 Diabetes Mellitus	2015
Emeritus Professor Philip Home	New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)	2015
Emeritus Professor Philip Home	New insulin glargine 300U/ml (Gla-300): glycaemic control and hypoglycaemia in insulin-naive people with Type 2 diabetes compared with glargine 100U/ml (Gla-100)	2015
Emeritus Professor Philip Home	New insulin glargine 300U/ml in people with Type 2 diabetes using basal insulin plus oral glucose lowering drugs compared with glargine 100U/ml (EDITION 2): less nocturnal hypoglycaemia and weight gain	2015
Emeritus Professor Philip Home	New insulin glargine 300U/ml in Type 2 diabetes using basal plus meal-time insulin: sustained glycaemic control and less hypoglycaemia compared with glargine 100U/ml (EDITION 1)	2015
Emeritus Professor Philip Home	One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension	2015
Emeritus Professor Philip Home	Pharmacokinetics and Pharmacodynamics of Biosimilar Insulins: Is Clamp Technology Fit for Purpose?	2015
Emeritus Professor Philip Home	Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?	2015
Emeritus Professor Philip Home	Predictors of HbA1c over 4 years in people with type 2 diabetes starting insulin therapies: The CREDIT study	2015
Emeritus Professor Philip Home	Sustained Glycemic Control and Less Hypoglycemia with New Insulin Glargine 300 U/ML: 1-Year Results in T2DM with Basal plus Mealtime Insulin (Edition 1)	2015
Emeritus Professor Philip Home	An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naive people with poorly controlled type 2 diabetes	2014
Emeritus Professor Philip Home	Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management Reflections From a Diabetes Care Editors' Expert Forum	2014
Emeritus Professor Philip Home	Cardiovascular outcomes and their relationship to risk factors and baseline disease over 4 years when starting insulin in type 2 diabetes: the CREDIT study	2014
Emeritus Professor Philip Home	Factors Associated With Weight Gain in People With Type 2 Diabetes Starting on Insulin	2014
Emeritus Professor Philip Home	Factors Associated With Weight Gain in People With Type 2 Diabetes Starting on Insulin. Diabetes Care 2014;37:2108-2113	2014
Emeritus Professor Philip Home	Four-year analysis of insulin dose and hypoglycaemia in the real-world treatment of type 2 diabetes: results from the CREDIT study	2014
Emeritus Professor Philip Home	Glycaemic control and hypoglycaemia with new insulin glargine 300 U/mL in people with type 1 diabetes (EDITION 4)	2014
Emeritus Professor Philip Home	Harmony 5-year 3 Results: albiglutide vs placebo and vs pioglitazone in triple therapy (background metformin and glimepiride) in people with type 2 diabetes	2014
Emeritus Professor Philip Home	Hypoglycaemia in people with type 2 diabetes achieving vs not achieving HbA1c target levels over 4 years in routine clinical practice: analysis of the CREDIT study	2014
Emeritus Professor Philip Home	Impact of biosimilar insulins on clinical practice: Meeting report	2014
Emeritus Professor Philip Home	Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges?	2014
Emeritus Professor Philip Home	Investigational new insulin glargine U300: glucose control and hypoglycaemia in people with Type 2 diabetes using a basal plus mealtime insulin regimen (EDITION I)	2014
Emeritus Professor Philip Home	Neues Insulin glargin U300: Blutzuckerkontrolle undHypoglykämiehäufigkeit bei Patienten mit Typ-2-Diabetes und einem Therapieschema aus Basal- undMahlzeiteninsulin (EDITION I) [New Insulin glargin U300: Blood Sugar Control and Hypoglycemic Frequency for Patients with Type-2-Diabetes and a Treatment Scheme from Basal- and Meal Insulin (EDITION I)]	2014
Emeritus Professor Philip Home	New insulin glargine 300 U/ml: efficacy and safety of flexible vs fixed dosing intervals in people with type 2 diabetes mellitus	2014
Emeritus Professor Philip Home	New insulin glargine 300 U/ml: glycaemic control and hypoglycaemia in insulin-naive people with type 2 diabetes mellitus (EDITION 3)	2014
Emeritus Professor Philip Home	New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)	2014
Emeritus Professor Philip Home	People with type 2 diabetes with lower HbA_1c using insulin experience fewer cardiovascular events and death: results from the CREDIT study	2014
Emeritus Professor Philip Home	Predictive and Explanatory Factors of Change in HbA_1c in a 24-Week Observational Study of 66,726 People With Type 2 Diabetes Starting Insulin Analogs	2014
Emeritus Professor Philip Home	Relationship of HbA_1c with body weight change over 4 years from starting insulin therapy in people with type 2 diabetes: the CREDIT study	2014
Emeritus Professor Philip Home	Response to Comment on Home et al. Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? Diabetes Care 2014; 37: 1499-1508	2014
Emeritus Professor Philip Home	RESPONSE TO COMMENT ON HOME ET AL. Predictive and Explanatory Factors of Change in HbA(1c) in a 24-Week Observational Study of 66,726 People With Type 2 Diabetes Starting Insulin Analogs. Diabetes Care 2014;37:1237-1245	2014
Emeritus Professor Philip Home	Safety, Tolerability, and Efficacy of Insulin Aspart in People with Type 2 Diabetes, as Biphasic Insulin Aspart or with Basal Insulin: Findings from the Multinational, Non-Interventional A₁chieve Study	2014
Emeritus Professor Philip Home	The vexed question of hypoglycaemia and health economics	2014
Emeritus Professor Philip Home	52-week efficacy of albiglutide vs placebo and vs pioglitazone in triple therapy (background metformin and glimepiride) in patients with type 2 diabetes: HARMONY 5 study	2013
Emeritus Professor Philip Home	A propensity score matched comparison of different insulin regimens 1 year after beginning insulin in people with type 2 diabetes	2013
Emeritus Professor Philip Home	Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)	2013
Emeritus Professor Philip Home	Biphasic Insulin Aspart 30 in Insulin-Naive People with Type 2 Diabetes in Non-western Nations: Results from a Regional Comparative Multinational Observational Study (A₁chieve)	2013
Emeritus Professor Philip Home	Comparison of National/Regional Diabetes Guidelines for the Management of Blood Glucose Control in non-Western Countries	2013
Emeritus Professor Philip Home	Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents	2013
Emeritus Professor Philip Home	Improved health status with insulin degludec compared with insulin glargine in people with type 1 diabetes	2013
Emeritus Professor Philip Home	Insulin Therapy and Cancer	2013
Emeritus Professor Philip Home	Methodology of a re-evaluation of cardiovascular outcomes in the RECORD trial: Study design and conduct	2013
Emeritus Professor Philip Home	New Insulin Glargine Formulation: Glucose Control and Hypoglycaemia in People with Type 2 Diabetes Using Basal and Mealtime Insulin (EDITION I)	2013
Emeritus Professor Philip Home	Observational research: an integral part of enhancing diabetes management in south-east Asia	2013
Emeritus Professor Philip Home	Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections from a Diabetes Care Editors' Expert Forum	2013
Emeritus Professor Philip Home	Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK	2013
Emeritus Professor Philip Home	Results of a re-evaluation of cardiovascular outcomes in the RECORD trial	2013
Emeritus Professor Philip Home	The effectiveness and safety of beginning insulin aspart together with basal insulin in people with type 2 diabetes in non-Western nations: Results from the A₁chieve observational study	2013
Emeritus Professor Philip Home	Validity of Meta-analysis in Diabetes: We Need to Be Aware of Its Limitations	2013
Emeritus Professor Philip Home	Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials	2012
Emeritus Professor Philip Home	Cardiovascular Disease and Oral Agent Glucose-Lowering Therapies in the Management of Type 2 Diabetes	2012
Emeritus Professor Philip Home	Diabetes complications and BMI in Asia, Africa, Europe, and Latin America: A1chieve baseline data	2012
Emeritus Professor Philip Home	Diabetes therapy and prevention of vascular damage	2012
Emeritus Professor Philip Home	Erratum to: Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials	2012
Emeritus Professor Philip Home	Factors influencing initial choice of insulin therapy in a large international non-interventional study of people with type 2 diabetes	2012
Emeritus Professor Philip Home	Global guideline for type 2 diabetes	2012
Emeritus Professor Philip Home	Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes	2012
Emeritus Professor Philip Home	Improving health outcomes in 2011 for people with type 2 diabetes: a report from a symposium held on the occasion of the International Diabetes Federation World Diabetes Congress, Dubai, 5-8 December 2011	2012
Emeritus Professor Philip Home	Macrovascular and microvascular outcomes after beginning of insulin versus additional oral glucose-lowering therapy in people with type 2 diabetes: an observational study	2012
Emeritus Professor Philip Home	Meta-analysis of maternal and neonatal outcomes associated with the use of insulin glargine versus NPH insulin during pregnancy	2012
Emeritus Professor Philip Home	Observational study of the association of first insulin type in uncontrolled type 2 diabetes with macrovascular and microvascular disease	2012
Emeritus Professor Philip Home	Profiles of cardiovascular risk in people with type 2 diabetes: baseline data from a1chieve study	2012
Emeritus Professor Philip Home	The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences	2012
Emeritus Professor Philip Home	A comparison of duration of first prescribed insulin therapy in uncontrolled type 2 diabetes	2011
Emeritus Professor Philip Home	A comparison of quality of life measured with the SF-36 for insulin degludec and insulin glargine in people with type 1 diabetes	2011
Emeritus Professor Philip Home	A meta-analysis of maternal outcomes in pregnant women using insulin glargine compared with NPH insulin	2011
Emeritus Professor Philip Home	An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-western countries: The A₁chieve study	2011
Emeritus Professor Philip Home	Biosimilar insulins	2011
Dr Latika Sibal Dr Sharad Agarwal Emeritus Professor Philip Home	Carotid intima-media thickness as a surrogate marker of cardiovascular disease in diabetes	2011
Emeritus Professor Philip Home	Factors associated with weight gain in type 2 diabetic patients starting on insulin: the CREDIT study	2011
Dr Stuart Little Professor James Shaw Emeritus Professor Philip Home	Hypoglycemic rates with basal insulin analogs	2011
Emeritus Professor Philip Home	Incidence and prevalence of unrecognized myocardial infarction in people with diabetes : a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in diabetes (RECORD) study	2011
Emeritus Professor Philip Home	Incidence and Prevalence of Unrecognized Myocardial Infarction in People With Diabetes: A substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study	2011
Emeritus Professor Philip Home	Insulin Degludec in Type 1 Diabetes A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine	2011
Emeritus Professor Philip Home	Quality standard for diabetes in adults	2011
Emeritus Professor Philip Home	Safety of PPAR agonists	2011
Emeritus Professor Philip Home	Should A1C targets be individualized for all people with diabetes? Arguments for and against	2011
Emeritus Professor Philip Home	Structured care for diabetes should cover a spectrum of areas	2011
Emeritus Professor Philip Home	A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study	2010
Emeritus Professor Philip Home	Duration of first insulin therapy in previously uncontrolled type 2 diabetes: Comparison of insulins glargine, detemir and NPH and association with glycemic control [abstract]	2010
Dr Shaikh Abdul Shakoor Dr Ali Aldibbiat Lorna Ingoe Dr Susan Campbell Dr Latika Sibal et al.	Endothelial Progenitor Cells in Subclinical Hypothyroidism: The Effect of Thyroid Hormone Replacement Therapy	2010
Emeritus Professor Philip Home	Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials	2010
Dr Latika Sibal Dr R Neely Emeritus Professor Philip Home	Friedewald equation underestimates low-density lipoprotein cholesterol at low concentrations in young people with and without Type 1 diabetes	2010
Emeritus Professor Philip Home	Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial	2010
Emeritus Professor Philip Home	How can observational trials inform and improve clinical practice?	2010
Emeritus Professor Philip Home	Insufficient evaluation of adverse events is not a proof of safety. Reply to LG Hemkens, U Grouven, R Bender, et al. [letter]	2010
Dr Latika Sibal Crispian Oates Emeritus Professor Philip Home	Lipoprotein associations with endothelial dysfunction and carotid intima-media thickness in young people with Type 1 diabetes	2010
Emeritus Professor Philip Home	Low-dose rosiglitazone plus metformin reduces risk of incident type 2 diabetes compared with placebo in people with impaired glucose tolerance	2010
Emeritus Professor Philip Home	Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine	2010
Emeritus Professor Philip Home	Observational studies: Going beyond the boundaries of randomized controlled trials	2010
Dr Reena Thomas Emeritus Professor Philip Home	Recommended management of type 1 diabetes with insulin	2010
Emeritus Professor Philip Home	Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: A pooled analysis of treat-to-target trials	2010
Dr Latika Sibal Dr Sharad Agarwal Emeritus Professor Philip Home	The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease	2010
Dr Latika Sibal Emeritus Professor Philip Home	A study of endothelial function and circulating asymmetric dimethylarginine levels in people with Type 1 diabetes without macrovascular disease or microalbuminuria	2009
Dr Umesh Dashora Dr Simon Ashwell Emeritus Professor Philip Home	An exploratory study of the effect of using high-mix biphasic insulin aspart in people with type 2 diabetes	2009
Dr Latika Sibal Dr Ali Aldibbiat Dr Sharad Agarwal Crispian Oates Dr Salman Razvi et al.	Circulating endothelial progenitor cells, endothelial function, carotid intima-media thickness and circulating markers of endothelial dysfunction in people with type 1 diabetes without macrovascular disease or microalbuminuria	2009
Emeritus Professor Philip Home	Combined randomised controlled trial experience of malignancies in studies using insulin glargine	2009
Emeritus Professor Philip Home	Comparison of a Multiple Daily Insulin Injection Regimen (Basal Once-Daily Glargine Plus Mealtime Lispro) and Continuous Subcutaneous Insulin Infusion (Lispro) in Type 1 Diabetes: A randomized open parallel multicenter study	2009
Emeritus Professor Philip Home	Estimating number-needed-to-treat with insulin glargine compared with NPH insulin to avoid a hypoglycaemic episode in people with type 2 diabetes mellitus: a meta-analysis	2009
Dr Latika Sibal Emeritus Professor Philip Home	Management of type 2 diabetes: NICE guidelines	2009
Emeritus Professor Philip Home	Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins	2009
Emeritus Professor Philip Home	Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial	2009
Emeritus Professor Philip Home	Rosiglitazone was noninferior to metformin plus sulfonylurea for CV events but increased risk for HF and fractures in type 2 diabetes	2009
Emeritus Professor Philip Home	Surgery and the prevention of limb loss in diabetes	2009
Emeritus Professor Philip Home	A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes	2008
Peter Curtis Emeritus Professor Philip Home	Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)	2008
Emeritus Professor Philip Home	HbA1c: The case for using estimated average glucose (eAG)	2008
Emeritus Professor Philip Home	Hepatic dysfunction and insulin insensitivity in type 2 diabetes mellitus: A critical target for insulin-sensitizing agents	2008
Emeritus Professor Philip Home	Impact of the UKPDS - An overview	2008
Emeritus Professor Philip Home	Injection site abscesses	2008
Dr Latika Sibal Dr Ali Aldibbiat Crispian Oates Dr Jolanta Weaver Professor James Shaw et al.	The influence of the presence of retinopathy on the circulating endothelial progenitor cell counts, endothelial function and carotid intima-media thickness in type I diabetes	2008
Dr Simon Ashwell Emeritus Professor Philip Home	Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetes	2008
Emeritus Professor Philip Home	A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with type 2 diabetes	2007
Emeritus Professor Philip Home	A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK	2007
Emeritus Professor Philip Home	Change in plasma glucose following exercise in type 1 diabetes: a comparison of three basal insulins	2007
Emeritus Professor Philip Home	Comment on: Nauck MA, Duran S, Kim D et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: A non-inferiority study. Diabetologia 50:259-267 [2]	2007
Dr Latika Sibal Emeritus Professor Philip Home	Counterpoint: A Diabetes Outcome Progression Trial (ADOPT): Good for sulfonylureas?	2007
Dr Ebaa Al-Ozairi Emeritus Professor Philip Home	Counterpoint: A Diabetes Outcome Progression Trial (ADOPT): Good for Sulfonylureas?	2007
Emeritus Professor Philip Home	Early retinopathy progression in four randomized trials comparing insulin glargine and Nph insulin	2007
Dr Latika Sibal Dr Ali Aldibbiat Dr Jolanta Weaver Dr Salman Razvi Crispian Oates et al.	Endothelial dysfunction and circulating endothelial progenitor cells in young people with type 1 diabetes	2007
Dr Latika Sibal Dr Ali Aldibbiat Dr Sharad Agarwal Dr Jolanta Weaver Dr Salman Razvi et al.	Endothelial dysfunction, carotid intima media thickness and circulating endothelial progenitor cells in young people with Type 1 diabetes	2007
Dr Umesh Dashora Dr Latika Sibal Dr Simon Ashwell Emeritus Professor Philip Home	Insulin glargine in combination with nateglinide in people with Type 2 diabetes: A randomized placebo-controlled trial	2007
Emeritus Professor Nick Europe-Finner Emeritus Professor John Gibson Emeritus Professor Philip Home Professor David Leaper Professor Roy Taylor et al.	Medical training in the UK: sleepwalking to disaster	2007
Emeritus Professor Philip Home Professor David Leaper Professor Roy Taylor	Modernising Medical Careers, Medical Training Application Service, and the Postgraduate Medical Education and Training Board: time for the emperors to don their clothes	2007
Dr Latika Sibal Janice Gebbie Emeritus Professor Philip Home	Risk factors for incidence and progression of diabetic retinopathy in people with Type 1 diabetes: a 9-year follow-up study	2007
Emeritus Professor Philip Home	Rosiglitazone evaluated for cardiovascular outcomes - An interim analysis	2007
Emeritus Professor Philip Home Peter Curtis	Rosiglitazone RECORD study: Glucose control outcomes at 18 months	2007
Dr Tim Butler Emeritus Professor Philip Home	The effect of the optimal use of rapid-acting insulin analogues on insulin secretion in Type 2 diabetes	2007
Dr Latika Sibal Dr Ali Aldibbiat Ian Harvey Dr Brian Shenton Dr Graham Holliman et al.	[abstract] Identification and quantification of circulating endothelial progenitor cells in individuals with Type 1 diabetes and non-diabetic controls	2006
Emeritus Professor Philip Home Peter Curtis	[abstract] Prolonged efficacity on 12 months of rosiglitazone given in association on ambulatory arterial stiffness in patients suffering type 2 diabetes	2006
Emeritus Professor Philip Home	A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-Naïve people with type 2 diabetes	2006
Emeritus Professor Philip Home	A digest of the Global Guideline for Type 2 Diabetes.	2006
Emeritus Professor Philip Home	A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies	2006
Dr Latika Sibal Janice Gebbie Emeritus Professor Philip Home	Cardiovascular risk factors predicting the development of distal symmetrical polyneuropathy in people with type 1 diabetes: A 9-year follow-up study	2006
Emeritus Professor Philip Home	Cost-effectiveness of CSII	2006
Emeritus Professor Philip Home	Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia	2006
Emeritus Professor Philip Home	Global Guideline for Type 2 Diabetes: Recommendations for standard, comprehensive, and minimal care	2006
Emeritus Professor Philip Home	Identifying the impact of diabetes research	2006
Dr Simon Ashwell Professor Rudy Bilous Dr Umesh Dashora Emeritus Professor Philip Home	Improved glycaemic control with insulin glargine plus insulin lispro: A multicentre, randomized, cross-over trial in people with Type 1 diabetes	2006
Emeritus Professor Philip Home	Insulin detemir: From concept to clinical experience	2006
Emeritus Professor Philip Home	Modelling lifetime metabolic progression and cost effectiveness of treatment strategies for type 2 diabetes - Reply	2006
Dr Simon Ashwell Janice Gebbie Emeritus Professor Philip Home	Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times	2006
Dr Latika Sibal Janice Gebbie Dr Umesh Dashora Dr Sharad Agarwal Emeritus Professor Philip Home et al.	Predicting the development of macrovascular disease in people with type 1 diabetes: A 9-year follow-up study	2006
Emeritus Professor Philip Home	Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes	2006
Emeritus Professor Philip Home	The authors' reply	2006
Emeritus Professor Philip Home	The diabetes epidemic and the developing world	2006
Emeritus Professor Philip Home	Time of evening administration of insulin detemir can be fitted to individual needs and lifestyle	2006
Dr Simon Ashwell Janice Gebbie Emeritus Professor Philip Home	Twice-daily compared with once-daily insulin glargine in people with type 1 diabetes using meal-time insulin aspart	2006
Emeritus Professor Philip Home	A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes	2005
Emeritus Professor Philip Home	Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes	2005
Emeritus Professor Philip Home	Global Guideline for Type 2 Diabetes	2005
Emeritus Professor Philip Home	Guidelines for the treatment and management of new-onset diabetes after transplantation	2005
Dr Robert Thomas Emeritus Professor Philip Home	Insulin therapy for people with Type 1 diabetes	2005
Peter Curtis Emeritus Professor Philip Home	Randomized controlled trial of the effect of rosiglitazone in combination therapy on ambulatory blood pressure in people with type 2 diabetes mellitus followed for 12 months	2005
Peter Curtis Emeritus Professor Philip Home	Rosiglitazone combination therapy lowers ambulatory blood pressure (ABP) over a twelve month period in patients with Type 2 diabetes mellitus	2005
Emeritus Professor Philip Home	Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): Study design and protocol	2005
Emeritus Professor Philip Home	The effect of improved post-prandial blood glucose control on post-prandial metabolism and markers of vascular risk in people with Type 2 diabetes	2005
Dr Simon Ashwell Janice Gebbie Emeritus Professor Philip Home	Comparison of insulin glargine injection at lunchtime, dinner-time and bedtime in people with Type 1 diabetes using mealtime insulin lispro	2004
Emeritus Professor Philip Home	Death from diabetes	2004
Emeritus Professor Philip Home	Diabetes Care in need	2004
Emeritus Professor Philip Home	Efficacy, insulin dose and antibody formation in a four-year trial comparing twice daily biphasic insulin aspart 30 with twice daily biphasic human insulin	2004
Emeritus Professor Philip Home	Glucose: sweetness and toxin	2004
Emeritus Professor Philip Home	Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: An evidence-based strategy to reduce the burden of late-developing diabetes complications	2004
Emeritus Professor Philip Home	Insulin Detemir Offers Improved Glycemic Control Compared with NPH Insulin in People with Type 1 Diabetes: A randomized clinical trial	2004
Emeritus Professor Philip Home	It's all about the people	2004
Emeritus Professor Philip Home	Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes	2004
Emeritus Professor Philip Home	Not the blank slate	2004
Emeritus Professor Philip Home	Prevention and management of foot problems in Type 2 diabetes. Also summarized as NICE guideline	2004
Emeritus Professor Philip Home	Principles for national and regional guidelines on cardiovascular disease prevention - A scientific statement from the World Heart and Stroke Forum	2004
Emeritus Professor Philip Home Peter Curtis	Rosiglitazone combination therapy improves ambulatory blood pressure: A 6-month substudy of the RECORD trial in people with type 2 diabetes	2004
Emeritus Professor Philip Home	Standardisation of glycated haemoglobin	2004
Emeritus Professor Philip Home	Standardisation of glycated haemoglobin [Editorial]	2004
Emeritus Professor Philip Home	Understanding the evidence	2004
Emeritus Professor Philip Home	A diabetes presence	2003
Emeritus Professor Philip Home	A guide to guide diabetes guideline development	2003
Emeritus Professor Philip Home	A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with Type 1 diabetes	2003
Emeritus Professor Philip Home	Diabetes beyond health care	2003
Emeritus Professor Philip Home	Going down: lipids and all that cholesterol	2003
Emeritus Professor Philip Home Dr Peter Senior	Hypertension in people with Type 2 diabetes: Knowledge-based diabetes-specific guidelines	2003
Emeritus Professor Philip Home	Issues relating to the early or earlier use of insulin in type 2 diabetes	2003
Emeritus Professor Philip Home	It's all kidneys	2003
Emeritus Professor Philip Home	PPAR- modulators: their role in diabetes care	2003
Emeritus Professor Philip Home	Prevention comes of age	2003
Emeritus Professor Philip Home	The challenge of poorly controlled diabetes mellitus	2003
Emeritus Professor Philip Home	The very centre of care	2003
Emeritus Professor Philip Home	Where next for IDF?	2003
Emeritus Professor Philip Home	A randomized, multicentre trial of insulin glargine versus NPH insulin in people with Type 1 diabetes	2002
Emeritus Professor Philip Home Dr Simon Ashwell	An overview of insulin glargine	2002
Emeritus Professor Philip Home	Clinical Guidelines and Evidence Review for Type 2 Diabetes	2002
Emeritus Professor Philip Home Rebecca Crow	Clinical guidelines and evidence review for Type 2 diabetes: management of blood glucose	2002
Emeritus Professor Philip Home	Considerations on blood glucose management in type 2 diabetes mellitus	2002
Emeritus Professor Philip Home	Expensive new drugs: NICE , or not so nice?	2002
Emeritus Professor Philip Home	Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes	2002
Emeritus Professor Philip Home	Organisation of Diabetes Care	2002
Emeritus Professor Philip Home	Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: A randomized trial in Type 1 and Type 2 diabetic patients	2002
Emerita Professor Sally Marshall Emeritus Professor Philip Home	Standardization of glycated haemoglobin [1]	2002
Emerita Professor Sally Marshall Emeritus Professor Philip Home	Standardization of glycated haemoglobin [2]	2002
Emeritus Professor Philip Home	The drug dilemma	2002
Dr Alison Gallagher Emeritus Professor Philip Home	The effect of insulin aspart on post-prandial metabolism and lipid profile in Type 2 diabetes	2002
Emeritus Professor Philip Home	The interaction between frequency of hypoglycaemia, single and multiplevascular complications and health utility	2002
Emeritus Professor Philip Home	Therapeutic targets in the management of type 1 diabetes	2002
Emeritus Professor Philip Home	Thiazolidenediones: increasing insulin sensitivity	2002
Emeritus Professor Philip Home	Biphasic insulin aspart and biphasic human insulin compared in Type 2 diabetic subjects	2001
Emeritus Professor Philip Home	Gestational impaired glucose tolerance does not increase perinatal mortality in a developing country: cohort study	2001
Emeritus Professor Philip Home	Insulin aspart safe for long-term treatment	2001
Dr Simon Ashwell Emeritus Professor Philip Home	Insulin glargine: The first clinically useful extended-action insulin analogue	2001
Emeritus Professor Philip Home	Interval between insulin injection and meal in relation to glycated haemoglobin	2001
Dr Alison Gallagher Emeritus Professor Philip Home	The effect of insulin aspart on postprandial metabolism and metabolic outcome in Type 2 diabetes	2001
Emeritus Professor Philip Home	Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial	2000
Emeritus Professor Philip Home	Insulin glargine - Viewpoint	2000
Emeritus Professor Philip Home	Postprandial hyperglycaemia: Mechanisms and importance	2000
Emeritus Professor Philip Home	Rapid-acting insulin analogues: When randomized clinical trial results do not help	2000
Emeritus Professor Sir George Sir George Alberti Professor Rudy Bilous Emeritus Professor Philip Home Torgrim Lauritsen	A desktop guide to Type 1 (insulin-dependent) diabetes mellitus	1999
Emeritus Professor Sir George Sir George Alberti Professor Rudy Bilous Emeritus Professor Philip Home Torgrim Lauritsen	A desktop guide to Type 2 diabetes mellitus	1999
Emeritus Professor Philip Home Dr Luis Barriocanal	Comparative pharmacokinetics and pharmacodynamics of the novel rapid- acting insulin analogue, insulin aspart, in healthy volunteers	1999
Emeritus Professor Philip Home	Insulin aspart	1999
Emeritus Professor Philip Home	Insulin aspart improves long-term glycaemic control in Type 1 diabetes - A randomized trial vs. human insulin	1999
Emeritus Professor Philip Home	Insulin glargine: The first clinically useful extended-acting insulin in half a century?	1999
Emeritus Professor Philip Home	Rapid-acting insulin secretagogues: a clinical need?	1999
Emeritus Professor Philip Home	Rapid-acting insulin secretagogues: a clinical need?	1999
Emeritus Professor Philip Home	Untitled - Foreword	1999
Emeritus Professor Philip Home Emeritus Professor Alan Murray	REPEATABILITY OF MEASUREMENTS AND SOURCES OF VARIABILITY IN TESTS OF CARDIOVASCULAR AUTONOMIC FUNCTION	1992